JP2022502492A - 骨髄増殖性疾患の治療法 - Google Patents

骨髄増殖性疾患の治療法 Download PDF

Info

Publication number
JP2022502492A
JP2022502492A JP2021540380A JP2021540380A JP2022502492A JP 2022502492 A JP2022502492 A JP 2022502492A JP 2021540380 A JP2021540380 A JP 2021540380A JP 2021540380 A JP2021540380 A JP 2021540380A JP 2022502492 A JP2022502492 A JP 2022502492A
Authority
JP
Japan
Prior art keywords
thiamine
patient
compound
myelofibrosis
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021540380A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022502492A5 (https=
JPWO2020068755A5 (https=
Inventor
ティマラ・ベリー
ジョン・フッド
カトリオナ・ジェイミーソン
カーティス・エル・スクリブナー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Impact Biomedicines Inc
Original Assignee
Impact Biomedicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69950867&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2022502492(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Impact Biomedicines Inc filed Critical Impact Biomedicines Inc
Publication of JP2022502492A publication Critical patent/JP2022502492A/ja
Publication of JP2022502492A5 publication Critical patent/JP2022502492A5/ja
Publication of JPWO2020068755A5 publication Critical patent/JPWO2020068755A5/ja
Priority to JP2024125670A priority Critical patent/JP2024161416A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2021540380A 2018-09-25 2019-09-24 骨髄増殖性疾患の治療法 Pending JP2022502492A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024125670A JP2024161416A (ja) 2018-09-25 2024-08-01 骨髄増殖性疾患の治療法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862736369P 2018-09-25 2018-09-25
US62/736,369 2018-09-25
US201862783076P 2018-12-20 2018-12-20
US62/783,076 2018-12-20
PCT/US2019/052608 WO2020068755A1 (en) 2018-09-25 2019-09-24 Methods of treating myeloproliferative disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024125670A Division JP2024161416A (ja) 2018-09-25 2024-08-01 骨髄増殖性疾患の治療法

Publications (3)

Publication Number Publication Date
JP2022502492A true JP2022502492A (ja) 2022-01-11
JP2022502492A5 JP2022502492A5 (https=) 2022-10-03
JPWO2020068755A5 JPWO2020068755A5 (https=) 2022-10-03

Family

ID=69950867

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021540380A Pending JP2022502492A (ja) 2018-09-25 2019-09-24 骨髄増殖性疾患の治療法
JP2024125670A Pending JP2024161416A (ja) 2018-09-25 2024-08-01 骨髄増殖性疾患の治療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024125670A Pending JP2024161416A (ja) 2018-09-25 2024-08-01 骨髄増殖性疾患の治療法

Country Status (14)

Country Link
US (2) US20220031699A1 (https=)
EP (1) EP3856169A4 (https=)
JP (2) JP2022502492A (https=)
KR (2) KR20210102192A (https=)
CN (1) CN113286584A (https=)
AU (1) AU2019346521B2 (https=)
BR (1) BR112021005518A2 (https=)
CL (1) CL2021000744A1 (https=)
IL (1) IL281736A (https=)
MA (1) MA53741A (https=)
MX (2) MX2021003450A (https=)
MY (1) MY209349A (https=)
SG (1) SG11202103019WA (https=)
WO (1) WO2020068755A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3856189A4 (en) * 2018-09-25 2022-06-29 Impact Biomedicines, Inc. Methods of treating myeloproliferative disorders
WO2020068755A1 (en) 2018-09-25 2020-04-02 Impact Biomedicines, Inc. Methods of treating myeloproliferative disorders
EP3923948A4 (en) 2019-02-12 2022-11-16 Impact Biomedicines, Inc. CRYSTALLINE SHAPES OF A JAK2 INHIBITOR
JP2024501640A (ja) * 2020-12-16 2024-01-15 インパクト バイオメディシンズ インコーポレイテッド フェドラチニブの投薬
MX2023009858A (es) 2021-02-25 2023-09-12 Impact Biomedicines Inc Uso de inhibidores de proteina de bromodominio y motivo extraterminal (bet) solo o en combinacion con fedratinib o ruxolitinib como tratamiento para una malignidad hematologica tal como la mielofibrosis.
WO2023044297A1 (en) 2021-09-14 2023-03-23 Impact Biomedicines, Inc. Fedratinib for treating myeloproliferative disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013541595A (ja) * 2010-11-07 2013-11-14 ターゲジェン インコーポレーティッド 骨髄線維症を処置するための組成物及び方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103626742B (zh) * 2005-11-01 2017-04-26 塔格根公司 激酶的联-芳基间-嘧啶抑制剂
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US20090093009A1 (en) * 2007-10-09 2009-04-09 Sum Chan Mass spectrometry method for measuring thiamine in body fluid
US20130102624A1 (en) * 2011-05-19 2013-04-25 John V. Schloss Early detection of thiamine deficiency
US10155987B2 (en) 2012-06-12 2018-12-18 Dana-Farber Cancer Institute, Inc. Methods of predicting resistance to JAK inhibitor therapy
WO2015081127A2 (en) 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
CA2936865A1 (en) * 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
HK1256638A1 (zh) * 2015-08-04 2019-09-27 Acceleron Pharma Inc. 用於治疗骨髓增生性病症的方法
WO2020068755A1 (en) 2018-09-25 2020-04-02 Impact Biomedicines, Inc. Methods of treating myeloproliferative disorders
EP3856189A4 (en) 2018-09-25 2022-06-29 Impact Biomedicines, Inc. Methods of treating myeloproliferative disorders
FR3092581A1 (fr) 2019-02-12 2020-08-14 Impact Biomedicines, Inc Formes cristallines d'un inhibiteur de jak2
EP3923948A4 (en) 2019-02-12 2022-11-16 Impact Biomedicines, Inc. CRYSTALLINE SHAPES OF A JAK2 INHIBITOR

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013541595A (ja) * 2010-11-07 2013-11-14 ターゲジェン インコーポレーティッド 骨髄線維症を処置するための組成物及び方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis p reviously treated with ruxoliti", LANCET HAEMATOL, vol. 4, JPN6023035661, 2017, pages 317 - 324, ISSN: 0005398827 *
"Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis A Randomized C", JAMA ONCOL, vol. 1(5), JPN6023035659, 2015, pages 643 - 651, ISSN: 0005144969 *
"The Janus Kinase 2 Inhibitor Fedratinib Inhibits Thiamine Uptake: A Putative Mechanism for the Onset", DRUG METAB DISPOS, vol. 42, JPN6023035660, 2014, pages 1656 - 1662, ISSN: 0005144968 *
"Thiamine deficiency appears uncommon in patients with Myeloproliferative Neoplasms", BRITISH JOURNAL OF HAEMATOLOGY, vol. 178, JPN6023035658, 2017, pages 327 - 340, ISSN: 0005144970 *

Also Published As

Publication number Publication date
AU2019346521B2 (en) 2025-05-08
WO2020068755A1 (en) 2020-04-02
AU2019346521A1 (en) 2021-05-20
MY209349A (en) 2025-07-03
CN113286584A (zh) 2021-08-20
BR112021005518A2 (pt) 2021-06-29
US11400092B2 (en) 2022-08-02
KR20250164332A (ko) 2025-11-24
US20220133724A1 (en) 2022-05-05
MX2023013844A (es) 2023-12-08
CL2021000744A1 (es) 2021-10-08
US20220031699A1 (en) 2022-02-03
MX2021003450A (es) 2021-07-16
EP3856169A4 (en) 2022-06-29
EP3856169A1 (en) 2021-08-04
KR20210102192A (ko) 2021-08-19
JP2024161416A (ja) 2024-11-19
MA53741A (fr) 2021-08-04
SG11202103019WA (en) 2021-04-29
IL281736A (en) 2021-05-31

Similar Documents

Publication Publication Date Title
US11400092B2 (en) Methods of treating myeloproliferative disorders
US11198731B2 (en) Combinations of cabozantinib and atezolizumab to treat cancer
Verstovsek Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis
US20120128665A1 (en) Preselection of subjects for therapeutic treatment based on hypoxic status
US8709419B2 (en) Combination therapy
Wei et al. A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma
TW202038964A (zh) 組合療法
JP2025029028A (ja) 骨髄増殖性疾患の治療法
JP7640033B2 (ja) ピリド［１，２－ａ］ピリミジノン類似体の使用
Khorramdelazad et al. A1, an innovative fluorinated CXCR4 inhibitor, redefines the therapeutic landscape in colorectal cancer
KR20160090814A (ko) Jak, cdk 및 pim의 억제제를 포함하는 조합 요법
US20140142128A1 (en) Methods of treating a disease or disorder associated with bruton's tyrosine kinase
EA051859B1 (ru) Способы лечения миелопролиферативных расстройств
HK40049559A (en) Methods of treating myeloproliferative disorders
EP4504202B1 (en) Combination therapies comprising gdc-6036 and gdc-0077 for the treatment of cancer
Yonesaka et al. Alternating therapy with osimertinib and afatinib blockades EGFR secondary mutation in EGFR-mutant lung cancer: a single-arm phase II trial
EA048287B1 (ru) Способы лечения миелопролиферативных расстройств
HK40118757A (zh) 用於治疗癌症的包含gdc-6036和gdc-0077的组合疗法
Matsumoto et al. P-623 Combination efficacy of bisphosphonate, zoledronate with imatinib mesylate (Gleevec) in small cell lung caner cell line

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220922

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230905

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240229

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240801

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240809

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260219